(Q35947437)

11 August 2017

1 reference

title

Confusion about measuring central nervous system effects (English)

1 reference

11 August 2017

author name string

Helmut G Madersbacher

series ordinal

1

1 reference

11 August 2017

publication date

1 December 2004

1 reference

11 August 2017

published in

Current urology reports

1 reference

11 August 2017

volume

5

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

442-446

1 reference

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

11 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11934-004-0068-9

Oxybutynin and cognitive dysfunction

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11934-004-0068-9

Functional expression and localization of P-glycoprotein at the blood brain barrier

21 January 2018

1 reference

12 December 2020

Drug-induced cognitive impairment in the elderly

1 reference

12 December 2020

Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells

1 reference

12 December 2020

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

1 reference

12 December 2020

Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy

1 reference

12 December 2020

Modulation of drug transporters at the blood-brain barrier

1 reference

12 December 2020

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system

1 reference

12 December 2020

New adverse effect of oxybutynin: "night terror".

1 reference

12 December 2020

Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers

1 reference

12 December 2020

Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

12 December 2020

Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione.

1 reference

12 December 2020

Trospium chloride: A quaternary amine with unique pharmacologic properties

1 reference

12 December 2020

Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors.

1 reference

12 December 2020

Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers

1 reference

12 December 2020

Discussion: functional role of M(1), M(2), and M(3) muscarinic receptors in overactive bladder

1 reference

12 December 2020

Tolterodine: a safe and effective treatment for older patients with overactive bladder

1 reference

12 December 2020

Advancements in pharmacologic management of the overactive bladder

1 reference

12 December 2020

Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity

1 reference

12 December 2020

[Neuropsychiatric adverse effects attributed to use of oxybutynin]

1 reference

12 December 2020

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

1 reference

12 December 2020

10.1007/S11934-004-0068-9

Identifiers

DOI

1 reference

release_2d226qb52vd2hk5oopjjq5pqxi

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2d226qb52vd2hk5oopjjq5pqxi

24 November 2022

mapped directly with Wikidata item

1 reference